Death Death/MI/RI Bleeding
Fig. 18. Proportion of patients with the primary end point of death (left group of bars), the composite end point of death, nonfatal reinfarction, or refractory ischemia (middle group of bars), and the safety end point of major bleeding (right group of bars) in the ASSENT 3 trial (92) for patients randomized to full-dose TNK-tPA plus enoxaparin (solid bars) vs reduced-dose TNK-tPA plus abciximab (shaded bars) vs full-dose TNK-tPA plus UFH (open bars).
Was this article helpful?